Login to Your Account

Aerpio study paid by $40M placement, rival Ang2 end-run effort

By Randy Osborne
Staff Writer

Thursday, March 16, 2017

Aerpio Pharmaceuticals Inc. has "a very different way" of activating Tie2, noted CEO Joseph Gardner. "What I don't know is whether an anti-angiopoietin-2 [Ang2] antibody activates Tie2, and how much activation you would get," he said.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription